compliance program guidance manual
LINK 1 ENTER SITE >>> Download PDF
LINK 2 ENTER SITE >>> Download PDF
File Name:compliance program guidance manual.pdf
Size: 3942 KB
Type: PDF, ePub, eBook
Category: Book
Uploaded: 10 May 2019, 17:43 PM
Rating: 4.6/5 from 711 votes.
Status: AVAILABLE
Last checked: 7 Minutes ago!
In order to read or download compliance program guidance manual ebook, you need to create a FREE account.
eBook includes PDF, ePub and Kindle version
✔ Register a free 1 month Trial Account.
✔ Download as many books as you like (Personal use)
✔ Cancel the membership at any time if not satisfied.
✔ Join Over 80000 Happy Readers
compliance program guidance manualFederal government websites often end in.gov or.mil. Before sharing sensitive information, make sure you're on a federal government site. Compliance Programs are made available to the public under the Freedom of Information Act. ( See FDA Freedom of Information Act Handbook for Requesting Information and Records from FDA. ) An alternative approach may be used as long as the approach satisfies the requirements of the applicable statutes and regulations. FDA's Compliance Programs are organized by the following program areas. Federal government websites often end in.gov or.mil. Before sharing sensitive information, make sure you're on a federal government site. Compliance Programs are made available to the public under the Freedom of Information Act. ( See FDA Freedom of Information Act Handbook for Requesting Information and Records from FDA ). An alternative approach may be used as long as the approach satisfies the requirements of the applicable statutes and regulations. It provides FDA personnel with information on internal procedures to be used in processing domestic and import regulatory and enforcement matters. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. Compliance Programs are made available to the public under the Freedom of Information Act. An alternative approach may be used as long as the approach satisfies the requirements of the applicable statutes and regulations. FDA’s Compliance Programs are organized by the following program areas. Chapter 42 - Blood and Blood Products. Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and Contractors- 7342.001 Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information OK.http://fainitelecommunication.com/public/editorfiles/dmr-es40v-manual.xml
- Tags:
- compliance program guidance manual, compliance program guidance manual for inspection of medical device manufacturers, compliance program guidance manual for fda staff, compliance program guidance manual cpgm, compliance program guidance manual 7356, compliance program guidance manual clinical investigators, compliance program guidance manual on pre-approval inspections, compliance program guidance manuals for medical device manufacturers, compliance program guidance manual for banks, bimo compliance program guidance manual, compliance program guidance manual, compliance program guidance manual, compliance program guidance manual fda, compliance program guidance manual cpgm, compliance program guidance manual chapter 42, compliance program guidance manual, compliance program guidance manual fda, compliance program guidance manual cpgm, compliance program guidance manual chapter 42.
As an overview, FDA’s “Compliance Programs” provide instructions to FDA personnel for conducting activities to evaluate industry compliance with the Federal Food, Drug, and Cosmetic Act (FFDCA) and other laws administered by FDA. This compliance program in particular covers inspections of businesses subject to the Preventive Controls for Human Foods (PCHF) rule that was issued under the FDA Food Safety Modernization Act (FSMA). Issued last fall, the CPGM is significant because it guided PCHF inspections until they were postponed due to the COVID-19 pandemic and will guide inspections going forward once they are resumed. Issuance of the CPGM marks a new phase in PCHF inspections and enforcement. Whether influencing policy making or confronting a threatened compliance action, Joe’s 25 years of FDA experience puts clients in the best position to succeed. In the private sector, Joe was on the ground floor when Congress developed the landmark FDA Food Safety Modernization Act (FSMA). Joe was also a leading voice for the food industry when the FDA developed regulations that all food companies must now follow. No one can help navigate the labyrinth of FDA’s FSMA regulations better than Joe and his team, and no one can better put your company in the driver’s seat when the FDA inspector knocks on your door for your first FSMA inspection. If a company finds itself in trouble with the FDA, they need someone with a deep insider’s understanding of what works and what doesn’t. Joe knows what the agency expects in the compliance arena, and the bar clients will be expected to meet. He can communicate his client’s position calmly and effectively to the FDA so the matter gets put behind them.He maintains close working relationships with senior FDA officials and has served as the Board Chair of the FDA Alumni Association. She has a keen understanding of the issues affecting the industry, from product development through production, distribution, and retail sale.http://djsjgs.com/uploadfile/20200922164635.xmlShe has a keen understanding of the issues affecting the industry, from product development through production, distribution, and retail sale. Her core practice involves helping companies ensure they are in compliance with regulations from federal agencies such as the Food and Drug Administration (FDA) and U.S. Department of Agriculture. Maile also provides strategic advice on public policy issues, frequently involving agency rulemakings. She translates her in-depth knowledge of FSMA into practical solutions for companies working on implementation strategies. She also is a Preventive Controls Qualified Individual (PCQI), as well as a Food Safety Preventive Controls Alliance Lead Instructor for the PCQI training. She helps clients navigate product recalls; government inspections; and other enforcement actions, such as Warning Letters and import detentions. Maile also advises clients on the development of label and advertising claims, as well as labeling requirements for foods and dietary supplements. Prior to joining Hogan Lovells, she served as a judicial clerk to the Honorable Charles F. Lettow of the U.S. Court of Federal Claims. Maile graduated with high honors from The George Washington University Law School, where she served as executive editor of The George Washington Law Review. Elizabeth works with every segment of the food industry, including manufacturers, distributors, retailers, restaurants, and food service operators; and their trade associations. Elizabeth’s work on behalf of food industry clients with the Food Safety Modernization Act (FSMA) since its inception and her understanding of Hazard Analysis Critical Control Point (HACCP) systems provides her with the experience and perspective needed as she counsels clients on how to comply with new requirements under the law. Elizabeth is a Preventive Controls Qualified Individual (PCQI) and has completed the FSPCA PCQI training. Her extensive knowledge enables clients to prevent and respond to enforcement actions such as Warning Letters, Import Alerts, and agency investigations. She helps clients in determining whether an RFR is necessary and whether a recall is warranted. If so, she helps manage the recall to minimize business impacts. Elizabeth provides real-time advice during factory inspections, helps clients prepare 483 responses, and drafts inspection manuals. She also assists clients in lawfully and creatively promoting their products; such as the development of labels, claims, and website and promotional campaigns. Elizabeth also supports clients in advertising disputes and with responses to FTC and Attorney General investigations. She also counsels clients on compliance with Consumer Product Safety Commission (CPSC) safety standards, testing and certification requirements, and reporting obligations. She advises clients on state and federal regulatory issues that arise throughout the entire food supply chain and production line, ranging from USDA and FDA enforcement actions and federal investigations to regulatory compliance, import and export issues, litigation support, comment preparation, advertising disputes, and labeling issues. Chris’s unique educational background and regulatory scientist experience provides valuable context to complex scientific issues as they relate to the governing regulatory requirements. A part-time student by night and a regulatory scientist by day, Chris worked throughout law school at a firm in Washington, D.C., focusing on product review, development, and post-marketing in the life sciences sphere, with experience handling matters under the Food and Drug Administration (FDA), the Department of Agriculture (USDA), and the Environmental Protection Agency (EPA), the Federal Trade Commission (FTC), the National Advertising Division (NAD), the Consumer Product Safety Commission (CPSC), as well as state regulatory bodies.https://cohemployeenews.com/images/complete-log4j-manual-pdf-download.pdf She advises clients on state and federal regulatory issues that may arise throughout the entire food production line from farm to table. Leigh also guides clients in consumer products industries as they navigate federal advertising laws and regulations. When she joined Hogan Lovells, Leigh brought with her more than five years of public policy experience. A part-time student by night and a law clerk by day, Leigh worked throughout law school at a firm in Washington, D.C., focusing on legislation and federal regulation affecting the energy industry. Before law school she served as a policy analyst for international affairs and climate change at the White House Council on Environmental Quality. All rights reserved. “Hogan Lovells” or the “firm” refers to the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses, each of which is a separate legal entity. Attorney advertising. Prior results do not guarantee a similar outcome. Powered By LexBlog. If you typed the URL directly, please make sure the spelling is correct. The page no longer exists. In this case, we profusely apologize for the inconvenience and for any damage this may cause. Compliance program effectiveness is a key variable DOJ takes into consideration when (1) making charging decisions and exercising prosecutorial discretion; (2) making sentencing recommendations, including calculating recommended fines; and (3) deciding whether to impose reporting requirements or appoint an outside compliance monitor as part of a corporate resolution. The Updated Compliance Guidance provides useful additional insights into prosecutors’ assessment criteria when making such decisions. The Updated Compliance Guidance, however, gives companies a clearer and more comprehensive sense of DOJ’s views on the design, implementation, and operation of effective compliance programs. Notably, in heavily regulated industries, such as healthcare and finance, DOJ continues to recommend that prosecutors refer to industry-specific regulations and agency guidance when assessing compliance program effectiveness. How has the company measured the effectiveness of the training?” The new guidance provides four additional factors for consideration: In December 2017, the DOJ unveiled a revised Corporate Enforcement Policy for the US Foreign Corrupt Practices Act (FCPA) under which companies that self-disclose misconduct, cooperate with investigations, and strengthen their compliance programs can secure credit in enforcement actions and may even avoid prosecution; since 2018, DOJ’s Criminal Division has been using that policy as guidance outside the FCPA context. In October 2018, AAG Benczkowski issued a memorandum explaining DOJ’s position on the role of monitorships in corporate compliance and enforcement considerations. In a November 2018 speech, Deputy Assistant General Rod Rosenstein reiterated that one objective of DOJ’s corporate enforcement policies is to “encourage companies to implement improved compliance programs.” The importance of effective compliance programs has been a point of emphasis in for DOJ’s Antitrust Division as well, as highlighted by AAG Makan Delrahim’s speech the day after the updated guidance was released in which he confirmed that the Division was considering a “range of options” to “further encourage the adoption of robust compliance programs.” The Updated Compliance Guidance, for example, mentions proactive risk assessment, monitoring, control testing, and periodic assessments of corporate culture as key tools to achieve such improvement. Taken another way, a compliance program that addresses “yesterday’s risks” is unlikely to be viewed as favorably “effective” today. For more information or to change your preferences, click here.This document, issued by FDA's Center for Drug Evaluation and Research (CDER), announces the long expected “systems” approach to drug manufacturing inspections. The workshops will be held in collaboration with the Consumer Healthcare Products Association (CHPA), and are intended to provide a regulatory perspective on the systems-based approach described below. The Workshops will be held in East Rutherford, New Jersey, on June 17, 2002, in San Juan, Puerto Rico, on July 15, 2002, and in Manhattan Beach, California, on August 5, 2002. For details on the workshops and registration information, see the announcement in the Federal register of March 29, 2002 (67 Fed.Reg. 15210). This guidance is relevant to any company involved in the manufacture of drugs, including manufacturers of bulk active pharmaceutical ingredients, intermediates and excipients. This is the first half of a broader coverage by FDA of all aspects of production and distribution of drugs and drug products. The Drug Manufacturing Inspections program addresses drug production, while the Drug Product Surveillance Program monitors the quality of drugs in distribution through surveillance activities such as sampling and analysis. The program is part of FDA's reprioritizing of resources. Although the general policy of biennial inspections is maintained under the program, it is the method by which those inspections are conducted that is modified by the guidance document. “Inspection” is defined under the guideline as “audit coverage of 2 or more systems, with mandatory coverage of the Quality System.” The compliance status of a facility will now be determined by sampling the compliance status of a variable number of systems (always including the Quality System) depending on the type of inspection being conducted. The overall cGMP evaluation of the inspected facility will be based on the sole evaluation of those systems that are actually inspected, as it will be assumed that system deficiencies apply across the board to all product lines manufactured at the site. Both types can be conducted either as full or abbreviated inspections depending on the circumstances. Characteristics of full and abbreviated inspections are as follows. This type of inspection is not routine, and thus is expected to be conducted only every third or fourth inspection cycle ( i.e., every 6 to 8 years). The full inspection normally includes coverage of at least four systems, including the Quality System. Such inspections can cover as little as two systems, the Quality System and one other. This type of inspection is used to investigate a specific problem that has come to the attention of the agency. This type of evaluation focuses on whatever system is related to the problems that give rise to the “cause.” The new approach applies to distributed prescription drug products, OTC drug products, approved products and products not requiring approval, as well as drug products used in clinical trials. Although the cGMP regulations are not directly applicable to active pharmaceutical ingredients (APIs), they are to be used as guidance for cGMP in API manufacture. Documented cGMP deficiencies provide the evidence for concluding that a system is not operating in a state of control. A firm is deemed out of control if any one of its systems is out of control.The guidance document can be found at. Previous iterations of the document (covered in our 2017 Mid-Year FCPA Update and May 3, 2019 Client Alert ) have been a valuable resource for companies as they design, maintain, and evaluate their corporate compliance programs, and the Update provides welcome insight into how DOJ’s thinking is evolving, particularly with respect to risk assessments, monitoring, and resources.Specifically, the Update calls for “ a reasonable, individualized determination in each case ” (emphasis added) of the effectiveness of a company’s compliance program, including its “size, industry, geographic footprint, and regulatory landscape,” with a dual focus on the program in effect at the time of the underlying conduct and the program in effect at the time of resolution. The Update also reflects the ongoing evolution and increasing sophistication of DOJ’s compliance program expectations, with an emphasis on allocating adequate resources to the compliance function, an increased focus on using ongoing, data-driven monitoring of risks to guide the design and implementation of the compliance program, and the inclusion of more granular guidance regarding DOJ’s expectations. Together, the questions seek to evaluate whether companies combine a thoughtfully designed program with the resources and culture necessary to create a program that works effectively in practice: The Update clarifies that prosecutors will consider these topics “both at the time of the offense and at the time of the charging decision and resolution.” For example, the Update now instructs prosecutors to consider why a company has “chosen to set up the compliance program the way that it has, and why and how the company’s compliance program has evolved over time,” and to consider “the reasons for the structural choices the company has made.” Other revisions include: The Compliance Program Update also now asks prosecutors to specifically consider how companies implement any learnings from their periodic reviews in policies, procedures, and controls, and increases the emphasis on lessons learned. For example, the Compliance Program Update asks prosecutors to consider whether the company tracks and incorporates any of these lessons into its periodic risk assessments. This approach is something many companies already do to remain familiar with relevant industry trends, enforcement actions, and good practices. For example, it instructs prosecutors to identify how companies publish their policies and procedures, track how their policies and procedures are accessed to determine which policies attract more attention than others, and ensure that employees have the tools needed to ensure compliance. This requirement reflects DOJ’s emphasis on ensuring that compliance program requirements are followed in practice.When evaluating the effectiveness of confidential reporting structures, such as hotlines, companies also are expected to take measures to test whether employees are aware of the hotline and feel comfortable using it, as well as to track reports from start to finish. Although DOJ recognizes that “the need for, and degree of, appropriate due diligence may vary” based on different factors, the revisions make clear that DOJ expects companies to take a thoughtful approach to their third-party relationships and that simply conducting cookie-cutter due diligence at the outset of a relationship will be insufficient to meet DOJ’s expectations. Accordingly, the Update suggests, companies should document the business rationale for utilizing a third party; conduct appropriate due diligence based on the third party’s particular risk profile; incorporate relevant anti-corruption compliance provisions in third-party contracts; and “engage in risk management of third parties throughout the lifespan of the relationship,” with ongoing monitoring and training. Clearly, the overwhelming number of DOJ resolutions in which third party agents, intermediaries, and distributors are the conduit for corrupt payments inform this Update. Practically, companies should review third parties annually and obtain from them a certification of compliance. The Compliance Program Update reiterates DOJ’s expectation that companies integrate newly acquired entities into their existing compliance program structures and internal controls in a timely and orderly fashion and particularly highlights the importance of post-acquisition audits. For example, it reinforces the need for companies to “foster a culture of ethics and compliance with the law at all levels of the company ” (emphasis added). This revised language continues a shift previously reported in our May 3, 2019 Client Alert, as DOJ broadens its compliance culture focus on the “tone at the top” to encompass the “tone at the middle,” and elsewhere. As with prior guidance, companies can use the Update as a benchmark to evaluate their existing compliance programs. Companies also should expect to see complementary revisions in DOJ’s template for “Attachment C,” which is appended to DOJ’s corporate resolutions and sets forth DOJ’s minimum expectations for corporate compliance programs in that context. Finally, companies also should consider complementary guidance from other U.S. agencies and international organizations—particularly the resources linked at the end of the Update, which in many instances reflect growing consensus regarding governmental expectations for corporate compliance programs. Please feel free to contact the Gibson Dunn lawyer with whom you usually work or any of the following members of the firm’s White Collar Defense and Investigations practice group: By continuing to browse our website, you consent to our use of cookies as set forth in our Cookie Policy. However you may visit Cookie Settings to customize your consent.Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works. The document, which was released without any accompanying public announcement or explanation, updates an April 30, 2019 version of the document ( 2019 Guidance ), as discussed in our May 9, 2019 Advisory. The 2019 Guidance updated original guidance published by the Division’s Fraud Section on February 8, 2017 (2017 Guidance), as discussed in our 2017 FCPA Mid-Year Review. Steptoe has more than 500 lawyers and other professional staff across offices in Beijing, Brussels, Chicago, Hong Kong, London, Los Angeles, New York, San Francisco, and Washington. For more information, visit www.steptoe.com. Powered By LexBlog. While the updated Evaluation of Corporate Compliance Programs (the “2020 Guidance”) contains no radical changes, it incorporates additional valuable insights regarding compliance best practices and reflects regulators’ increasing expectations of corporate compliance programs. This guidance provided prosecutors with an extensive list of compliance-related questions to ask companies under investigation, but included limited overall context for assessing the quality of a corporate compliance program.Within each of these three overarching questions, DOJ identified several sub-categories. For example, with respect to a program’s design, DOJ focused on risk assessment, development and review of policies and procedures, training and communication, confidential reporting structure and investigation process, third-party management, and handling of mergers and acquisitions. When it comes to compliance, one size definitely does not fit all. Continuing to move away from the antiquated model of a generic, “off-the-shelf” compliance program, the 2020 Guidance doubles down on the importance of risk assessments. It underscores the importance of prosecutors understanding each company’s unique circumstances and how they have influenced the development of its compliance program. For example, prosecutors “should endeavor to understand why the company has chosen to set up the compliance program the way that it has, and why and how the company’s compliance program has evolved over time.” The 2020 Guidance also places greater emphasis on the adequacy of compliance resources, which of course is essential for any program’s effective functioning. Regarding a compliance program’s application (the second key question above), DOJ elaborated that prosecutors should ask whether the program is “adequately resourced and empowered to function effectively.” Put differently, even the most artfully constructed program is doomed to fail without sufficient funding, qualified compliance personnel, and widespread support throughout all levels of an organization. In that regard, DOJ also now calls for considering specifically how compliance personnel are trained. Additionally, DOJ asks whether the enhancement and evolution of a company’s compliance program over time is “based upon continuous access to operational data and information across functions.” For many companies, this may pose a challenge. To be effective, a compliance program must regularly be reviewed and enhanced, including to address adequately ever-changing risks. DOJ endorses such review and enhancement based not only on operational data, as noted above, but also “lessons learned” from a company’s experience and that of others operating in the same industry and geographies. Under the 2020 Guidance, prosecutors also will scrutinize whether a company’s periodic reviews actually have led to meaningful changes in its compliance program. DOJ again underscores the value of careful oversight of any third-party agents that act on a company’s behalf.The updated guidance expressly recognizes that pre-transaction due diligence may be limited or constrained in certain circumstances.DOJ makes explicit the already-standard practice that prosecutors should consider a company’s compliance program “both at the time of the offense and at the time of the charging decision and resolution.” As we discussed in a recent article, companies are confronting new compliance risks while also making difficult decisions about compliance priorities and the allocation of limited resources as they grapple with the effects of the global pandemic. If anything, ensuring that a compliance program is effective is even more essential amidst such unprecedented disruptions. As companies contend with these extraordinary challenges, they would be well advised to consider carefully the 2020 Guidance, which reflects numerous best practices and recent developments in the field. At the same time, regulators hopefully will recognize how companies practically must temper aspirations of compliance perfection in light of real-world constraints. Districts should submit an to the CDER OC Division of Supply Chain Integrity (DSCI) mailbox and include PDMA Information in the subject heading when any non-violative (NAI or VAI) investigative reports and Establishment Inspection Reports (EIRs) conducted concerning enforcement of the Prescription Drug Marketing Act (PDMA) are available in FACTS or Turbo EIR. The District should scan and submit to reports received from any source concerning drug sample theft, loss, falsification, or diversion. CDER OC will input the reports into the CDER PDMA database. The District should routinely update the IOM with the name and phone number for the District s PDMA liaison contact. DATA REPORTING - Use PAC for all assignments directly generated by headquarters and field offices. This program also provides general guidance concerning inspection of firms for compliance with recordkeeping and monitoring systems required under the PDMA.Provisions 4 and 7 are relevant to this program. More specifically, PDMA in part regulates the storage, handling and distribution of prescription drug samples by firms via mail, common carrier, and delivery by representatives to licensed practitioners or pharmacies of hospitals or other health care entities. The inspectional aspects of this compliance program are focused on compliance with drug sample provisions.It is also recommended that they obtain PDMA training and read the preamble to the final rule and the regulations implementing PDMA prior to the assignment or inspection 2. Coordination with the Office of Criminal Investigations (OCI) All reports received from any source concerning prescription drug sample theft, loss, falsification, or diversion should be referred to the CDER Division of Supply Chain Integrity (DSCI) for inclusion into the CDER PDMA database. As agreed with OCI, any reports that will not be investigated by that office will be returned to DSCI, who will issue a follow-up assignment to the appropriate district office.